Table 5.
IL-1 blockade with trials of anti-IL-1 monoclonal antibodies*
| Study name (Phase) | ClinicalTrials.gov identifiers |
|---|---|
| Anti-IL-1β trials | |
| Early and established rheumatoid arthritis | NCT00487825; NCT00784628; NCT00505089; NCT00619905; NCT00619905; NCT00424346; NCT00471198; NCT00380744 |
| Gout flares in patients refractory to standard treatment (or contraindicated) | NCT00798369; NCT00819585; NCT01362608; NCT00927810; NCT01431638; NCT01080131; NCT01029652; NCT01470989; NCT01356602; NCT00663169; NCT01194921; NCT01160016; NCT01593527 |
| Polymyalgia rheumatica | NCT01364389 |
| Osteoarthritis of the knee (intra-articular) | NCT01160822 |
| Systemic-onset juvenile idiopathic arthritis | NCT00426218; NCT00889863; NCT00886769 |
| Schnitzler syndrome | NCT01276522; NCT00504595 |
| Familial Mediterranean fever | NCT01148797; NCT01088880 |
| Cryopyrin-associated periodic syndrome | NCT01576367; NCT01105507; NCT00991146; NCT01302860; NCT00685373; NCT00770601; NCT01213641; NCT00465985; NCT00487708 |
| Hyper-IgD syndrome | NCT01303380 |
| TNF receptor-associated periodic syndrome | NCT01242813 |
| Type 2 diabetes | NCT01068860; NCT00605475; NCT00900146; NCT01144975; NCT00541983; NCT01066715; NCT00513214; NCT00942188 |
| Type 2 pre-diabetic state | NCT00995930 |
| Proliferative diabetic retinopathy | NCT01589029 |
| Wet age-related macular degeneration | NCT00503022 |
| Arterial function in atherosclerosis in type 2 diabetes | NCT00995930 |
| Cardiovascular risk reduction in type 2 diabetes (CANTOS trial) | NCT01327846 |
| Chronic obstructive pulmonary disease | NCT00581945 |
| Type 1 diabetes | NCT01322321; NCT00998699 |
| Urticarial vasculitis | NCT01170936 |
| Pyoderma gangrenosum | NCT01302795 |
| Dry eye syndrome | NCT01250171 |
| Acne vulgaris | NCT01498874 |
| Anti-IL-1α trials‡ | |
| Moderate to severe acne vulgaris (Phase II) | NCT01474798 |
| Moderate to severe plaque psoriasis (Phase II) | NCT01384630 |
| Reducing restenosis in peripheral artery revascularization (Phase II) | NCT01270945 |
| Subjects with advanced haematological malignancies (Phase I) | NCT01260545 |
| Dose escalation in patients with advanced cancer (Phase I) | NCT01021072 |
| Patients with type 2 diabetes (Phase I) | NCT01427699 |
CANTOS, Canakinumab Anti-inflammatory Thrombosis Outcome Study; IL-1, interleukin-1; TNF, tumour necrosis factor.
*
Includes the following monoclonal antibodies neutralizing IL-1β: canakinumab, gevokizumab and LY2189102.
‡
All studies using MABp1, a naturally occurring monoclonal antibody neutralizing IL-1α.